Emerging treatment strategies for polycystic ovary syndrome women with obesity: Focus on glucagon-like peptide-1 receptor agonists

Journal of Diabetes and its Complications, Journal Year: 2024, Volume and Issue: 38(11), P. 108872 - 108872

Published: Sept. 17, 2024

Language: Английский

---

Exercise Training Counteracts Compromised Mitochondrial Capacity Induced by Energy Restriction in Prediabetics in a Sex‐Dependent Manner

Scandinavian Journal of Medicine and Science in Sports, Journal Year: 2024, Volume and Issue: 34(12)

Published: Nov. 27, 2024

ABSTRACT The objective of this randomized controlled trial was to examine if exercise training can counteract energy restriction‐induced impairment mitochondrial capacity in skeletal muscle 55–70‐years people with prediabetes and metabolic syndrome. potential impact sex explored. Fifty sedentary men women syndrome (age: 61 ± 6 (±SD) years, BMI: 29.6 4.7 kg·m −2 , body fat content: 37.5% 8.2% VO 2max : 22.3 5.7 mL·min −1 ·kg ) were either dietary advice (EX‐DI) or only (DI). Dietary aimed induce weight loss improve glycemic control. Exercise consisted 32 2 mixed 30–60 min sessions recreational small‐sided soccer distributed across 16 weeks. Maximal activity protein abundance key regulatory enzymes determined m. vastus lateralis pre‐ post‐intervention. Muscle glycogen content also determined. (DI), impaired ( p < 0.001) citrate synthase (CS), 3‐hydroxyacyl‐CoA dehydrogenase (HAD) maximal by 18% 43% 23% 19%, respectively. When combined training, no CS HAD detectable. Superoxide dismutase (SOD2) expression declined 0.05) DI remained unchanged EX‐DI. In terms differences, a decrease both EX‐DI observed exclusively (all 0.05). conclusion, weeks counteracts function 55‐ 70‐year‐old

Language: Английский

---

Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?

Medicina, Journal Year: 2024, Volume and Issue: 60(12), P. 2030 - 2030

Published: Dec. 9, 2024

Chronic respiratory disorders are the third leading cause of mortality globally. Consequently, there is a continuous pursuit effective therapies beyond those currently available. The therapeutic potential glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide/GLP-1 (GIP/GLP-1) receptor agonists extends regulation glycemia, including glucometabolic, cardiovascular, renal effects, rendering them viable candidates, due to their mechanisms action, for possible treatment disorders. This manuscript aims provide comprehensive evaluation evidence on direct (cellular) indirect (metabolic) actions GLP-1 GIP/GLP-1 within pulmonary systems. In addition, it examines efficacy in addressing prevalent disorders, specifically chronic obstructive disease (COPD), asthma, pneumonia, sleep apnea, hypertension, lung cancer, transplantation. Finally, seeks identify avenues further focused research this field.

Language: Английский

---

Diabetes: Recent Advances and Future Perspectives

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2875 - 2875

Published: Dec. 18, 2024

Diabetes is a chronic metabolic disorder distinguished by persistent hyperglycemia [...]

Language: Английский

---